The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine.

Center for Cognitive and Molecular Neuroscience 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Group of Neuropharmacology and Neurophysiology Division of Neuroscience The Bonoi Academy of Science and Education Chapel Hill NC USA

Institute for Translational Medicine on Molecular Function and Artificial Intelligence Imaging Affiliated Foshan Hospital of Sun Yat sen University Foshan Guangdong China

International Scientific Information Inc Melville NY USA

Zobrazit více v PubMed

Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11. PubMed PMC

World Health Organization (WHO) Novel Coronavirus (2019-nCoV) Situation Report-1. Jan 21, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.

World Health Organization (WHO) Coronavirus (COVID-19) https://covid19.who.int.

BASE Medicine Task Force. COVID-19: Facts and recommendations from A to Z. Sci Insigt. 2020;33(1):138–58.

Zumla A, Chan JF, Azhar EI, et al. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–47. PubMed PMC

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Drug Discov Ther. 2020;14(1):58–60. PubMed

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. PubMed

Porter KR, Raviprakash K. DNA vaccine delivery and improved immunogenicity. Curr Issues Mol Biol. 2017;22:129–38. PubMed

Lazo L, Valdes I, Guillén G, et al. Aiming at the heart: The capsid protein of dengue virus as a vaccine candidate. Expert Rev Vaccines. 2019;18(2):161–73. PubMed

Iavarone C, O’hagan DT, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16(9):871–81. PubMed

Verch T, Trausch JJ, Shank-Retzlaff M. Principles of vaccine potency assays. Bioanalysis. 2018;10(3):163–80. PubMed

Pharmaceutical Business Review. Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial. https://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial/

Safety and immunogenicity study of 2019-nCoV Vaccine (mRNA-1273) to prevent SARS-CoV-2 Infection. ClinicalTrials.gov Identifier: NCT04283461. https://clinicaltrials.gov/ct2/show/NCT04283461.

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–44. PubMed PMC

Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2) pii: taaa021. PubMed PMC

Zarghampoor F, Azarpira N, Khatami SR, et al. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231–38. PubMed

World Health Organization (WHO) Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.

Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020 [Epub ahead of print] PubMed PMC

Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020 [Epub ahead of print] PubMed PMC

Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–48. PubMed PMC

Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–52. PubMed PMC

Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963. PubMed PMC

Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol. 2017;1499:109–21. PubMed

Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines. 2015;14(2):221–34. PubMed

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2019;9(11):1319–30. PubMed PMC

Kramps T, Elbers K. Introduction to RNA Vaccines. Methods Mol Biol. 2017;1499:1–11. PubMed

Yuen KS, Ye ZW, Fung SY, et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. PubMed PMC

Cascella M, Rajnik M, Cuomo A, et al. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Jan, Features, evaluation and treatment coronavirus (COVID-19) https://www.ncbi.nlm.nih.gov/books/NBK554776/ PubMed

Zarghampoor F, Azarpira N, Khatami SR, et al. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231–38. PubMed

Reichmuth AM, Oberli MA, Jaklenec A, et al. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319–34. PubMed PMC

Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. PubMed PMC

Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) – recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–11. PubMed

Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–63. PubMed PMC

Zhou J, Fang L, Yang Z, et al. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach. FASEB J. 2019;33(12):14575–87. PubMed

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8. PubMed PMC

Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 [Epub ahead of print] PubMed PMC

Klasse PJ. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology. 2007;369(2):245–62. PubMed PMC

Magnus C, Rusert P, Bonhoeffer S, et al. Estimating the stoichiometry of human immunodeficiency virus entry. J Virol. 2009;83(3):1523–31. PubMed PMC

Shang J, Wan Y, Liu C, et al. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. PLoS Pathog. 2020;16(3):e1008392. PubMed PMC

Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI J. 2020;19:410–17. PubMed PMC

Rosenberg Y, Sack M, Montefiori D, et al. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. PLoS One. 2015;10(3):e0120451. PubMed PMC

Uthayakumar D, Paris S, Chapat L, et al. Non-specific effects of vaccines illustrated through the BCG example: From observations to demonstrations. Front Immunol. 2018;9:2869. PubMed PMC

Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol. 2007;28(6):702–7. PubMed

Lim B, Lee K. Stability of the osmoregulated promoter-derived proP mRNA is posttranscriptionally regulated by RNase III in Escherichia coli. J Bacteriol. 2015;197(7):1297–305. PubMed PMC

Schlake T, Thess A, Thran M, Jordan I. mRNA as novel technology for passive immunotherapy. Cell Mol Life Sci. 2019;76(2):301–28. PubMed PMC

Knights AJ, Nuber N, Thomson CW, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009;58(3):325–38. PubMed PMC

Ohto T, Konishi M, Tanaka H, et al. Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles. Biol Pharm Bull. 2019;42(2):299–302. PubMed

Peck KM, Lauring AS. Complexities of viral mutation rates. J Virol. 2018;92(14):e01031–17. PubMed PMC

Pepini T, Pulichino AM, Carsillo T, et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: Implications for vaccine design. J Immunol. 2017;198:4012–24. PubMed PMC

Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307–36. PubMed

van den Boogert MAW, Rader DJ, Holleboom AG. New insights into the role of glycosylation in lipoprotein metabolism. Curr Opin Lipidol. 2017;28(6):502–6. PubMed

Breloy I, Hanisch FG. Functional roles of O-glycosylation. Molecules. 2018;23(12):3063. PubMed PMC

Watanabe Y, Bowden TA, Wilson IA, Crispin M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj. 2019;1863(10):1480–97. PubMed PMC

Schulze IT. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis. 1997;176(Suppl 1):S24–28. PubMed

Vigerust DJ, Shepherd VL. Virus glycosylation: Role in virulence and immune interactions. Trends Microbiol. 2007;15(5):211–18. PubMed PMC

Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9(1):601–4. PubMed PMC

Behrens AJ, Struwe WB, Crispin M. Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. Expert Rev Proteomics. 2017;14(10):881–90. PubMed PMC

Watanabe Y, Allen JD, Wrapp D, et al. Site-specific analysis of the SARS-CoV-2 glycan shield. BioRxiv. 2020.03.26.010322. https://www.biorxiv.org/content/10.1101/2020.03.26.010322v1. PubMed DOI PMC

Mehta N, Alter G. Opportunities to exploit antibody glycosylation in vaccination. Future Virol. 2017;12:325–28.

Lundin KE, Gissberg O, Smith CI. Oligonucleotide therapies: The past and the present. Hum Gene Ther. 2015;26(8):475–85. PubMed PMC

Pascolo S. Vaccination with messenger RNA (mRNA) Handb Exp Pharmacol. 2008;183:221–35. PubMed

Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives

Long-Term Respiratory and Neurological Sequelae of COVID-19

Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide